Abemaciclib Shows Significant Benefit for HR-positive HER2-negative Patients with Advanced Breast Cancer
Really remarkable data and I think extremely encouraging for our patients with early-stage high-risk HR-positive HER2-negative breast cancer, says Hope Rugo, Professor of Medicine and Director of Breast Oncology, in this interview. She gives her perspective and main clinical conclusion from the analysis of abemaciclib vs standard endocrine therapy in the adjuvant setting for patients with high-risk early-stage hormone receptor-positive HER2-negative breast cancer.
